Ignite Creation Date:
2025-12-24 @ 5:36 PM
Ignite Modification Date:
2026-01-03 @ 11:10 PM
Study NCT ID:
NCT02489968
Status:
COMPLETED
Last Update Posted:
2018-09-06
First Post:
2015-05-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-05-12
Start Date Type:
ACTUAL
Primary Completion Date:
2016-11-18
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-06-16
Completion Date Type:
ACTUAL
First Submit Date:
2015-05-27
First Submit QC Date:
None
Study First Post Date:
2015-07-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-11-16
Results First Submit QC Date:
None
Results First Post Date:
2018-09-06
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-09-03
Last Update Post Date:
2018-09-06
Last Update Post Date Type:
ACTUAL